InsidersTradesSigma
Follow the PERRIGO Co plc stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, PERRIGO Co plc has logged 195 reports. Market capitalisation: €1.5bn. The latest transaction was disclosed on 9 July 2026 (Levée d'options). Among the most active insiders: Bezerra Eduardo Guarita. Every trade is openly available.
195
Insider Decl.
n/a
Thresholds
€4m
27 ops.
Buy Volume
€10m
14 ops.
Sell Volume
31Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 23,544 of 29,062 companies
30.0
score / 100
Value39
Quality21
FCF yld7.2%
Earn yld-71%
EV/EBITDA·
ROE-49%
Gross mgn35%
Net mgn-34%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 9 July 2026
Declarations195 total
737 shares@ US$10.520.0005% mcap3.6% of flowOrdinary SharesSEC:0001585364-26-000112:0
385 shares@ US$10.520.0003% mcap1.9% of flowOrdinary SharesSEC:0001585364-26-000112:1
15,660 shares@ US$10.520.011% mcap58.8% of flowOrdinary SharesSEC:0001585364-26-000114:0
8,175 shares@ US$10.520.0059% mcap30.7% of flowOrdinary SharesSEC:0001585364-26-000114:1
1,843 shares@ US$10.520.0013% mcap6.9% of flowOrdinary SharesSEC:0001585364-26-000114:2
963 shares@ US$10.520.0007% mcap3.6% of flowOrdinary SharesSEC:0001585364-26-000114:3
976 sharesOrdinary SharesSEC:0001585364-26-000093:0
469 sharesOrdinary SharesSEC:0001585364-26-000093:1
6,690 shares@ US$10.830.0047% mcap62.8% of flowOrdinary SharesSEC:0001585364-26-000077:0
1,835 shares@ US$10.830.0013% mcap17.2% of flowOrdinary SharesSEC:0001585364-26-000077:1
2,867 shares@ US$10.830.0020% mcap73.4% of flowOrdinary SharesSEC:0001585364-26-000079:0
1,037 shares@ US$10.830.0007% mcap26.6% of flowOrdinary SharesSEC:0001585364-26-000079:1
9,175 shares@ US$10.830.0064% mcap5.6% of flowOrdinary SharesSEC:0001585364-26-000081:0
2,235 shares@ US$10.830.0016% mcap1.4% of flowOrdinary SharesSEC:0001585364-26-000081:1
3,507 shares@ US$10.840.0022% mcap19.4% of flowOrdinary SharesSEC:0001585364-26-000056:1
3,507 shares@ US$10.840.0022% mcap19.4% of flowOrdinary SharesSEC:0001585364-26-000050:1
5,122 shares@ US$10.840.0032% mcap5.4% of flowOrdinary SharesSEC:0001445728-26-000002:1
3,507 shares@ US$10.840.0022% mcap1.7% of flowOrdinary SharesSEC:0001585364-26-000052:1
7,305 shares@ US$10.840.0035% mcap5.3% of flowOrdinary SharesSEC:0001585364-26-000075:0
7,305 shares@ US$10.840.0035% mcap35.3% of flowOrdinary SharesSEC:0002060300-26-000006:0
10,669 shares@ US$10.840.0052% mcap18.4% of flowOrdinary SharesSEC:0001445728-26-000002:0
7,305 shares@ US$10.840.0035% mcap50.0% of flowOrdinary SharesSEC:0001585364-26-000054:0
3,066 shares@ US$10.720.0015% mcap14.7% of flowOrdinary SharesSEC:0002060300-26-000004:0
7,305 shares@ US$10.840.0035% mcap8.6% of flowOrdinary SharesSEC:0001625377-26-000002:0
7,305 shares@ US$10.840.0035% mcap50.0% of flowOrdinary SharesSEC:0001585364-26-000056:0
25 of 195 declarations
关于 PERRIGO Co plc
Perrigo Company plc（股票代码：PRGO）是一家在美国纽约证券交易所上市的公司，对于关注美国证券交易委员会（SEC）Form 4内部交易和美国消费者健康股票的投资者而言具有重要意义。尽管Perrigo在爱尔兰注册成立，公司总部设在都柏林，但其投资者基础、信息披露情况和运营足迹与美国紧密相连，该公司在美国拥有主要的制造和商业业务。该业务的历史可追溯到1887年，当时Luther Perrigo开始为乡村商店包装和分销专利药品和家居用品。这一传统至今仍塑造着公司作为经济实惠、广泛分销的自我护理产品领域规模化参与者的身份。（[perrigo.com](https://www.perrigo.com/history-convenient-healthy-solutions?utm_source=openai)) 如今，Perrigo已成为消费者自我护理产品和非处方健康与保健解决方案的领先供应商。其产品组合涵盖非处方药、口腔护理、婴儿配方奶粉、女性健康、护肤、消化健康、戒烟及相关自我护理类别。SEC文件显示，Perrigo历来围绕消费者自我护理部门组织其业务，最近的报告反映了公司持续推动其结构与商业运营模式更紧密地结合。这一点很重要，因为Perrigo的经济效益取决于其在自有品牌和品牌产品方面的广泛类别覆盖、监管执行和制造规模。（[sec.gov](https://www.sec.gov/Archives/edgar/data/0001944048/000194404825000118/final2024annualreport.pdf?utm_source=openai)) 竞争定位是Perrigo的关键优势之一。该公司称自己是美国最大的非处方自我护理产品制造商（按销量计），拥有11家美国制造工厂以及高比例的国内采购和生产。这种规模使Perrigo在与零售商的合作中拥有影响力，有助于保护供应可靠性，并支持其在价格、可用性和信任至关重要的类别中保持自有品牌领导地位。（[investor.perrigo.com](https://investor.perrigo.com/2025-05-07-Perrigo-Reports-First-Quarter-2025-Financial-Results-From-Continuing-Operations?utm_source=openai)) 其产品系列包括日常必需品而非处方药：咳嗽、感冒和过敏治疗；止痛护理；消化健康；口腔护理；婴儿护理；女性健康；以及其他自我护理类别。Perrigo还涉足婴儿营养领域，这是近期运营的重点。一个值得关注的面向消费者的里程碑是Opill®在美国的推出，这是该国首个非处方口服避孕药，通过大型零售网络推出。此次推出突显了Perrigo在高知名度类别中结合科学、监管和商业能力的能力。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1585364/000158536424000066/cy24q1ex991pressrelease.htm?utm_source=openai)) 最近的发展表明，该公司正处于转型期，而非静态的防御性态势。2025年，Perrigo宣布对其婴儿配方奶粉和口腔护理业务进行战略审查，并签署了一项剥离其Dermacosmetics业务的协议；该交易于2026年完成。管理层还强调了简化议程、新的运营模式和旨在稳定业绩并提高长期利润的成本节约措施。对于投资者而言，PRGO将防御性消费者健康敞口与有意义的投资组合重新定位故事结合在一起。（[investor.perrigo.com](https://investor.perrigo.com/2025-11-05-Perrigo-to-Conduct-Strategic-Review-of-its-Infant-Formula-Business?utm_source=openai))
